更新于：2024-07-01
Octreotide Acetate
醋酸奥曲肽
更新于：2024-07-01
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看首次获批时间轴
结构
分子式C51H70N10O12S2 |
InChIKeyXQEJFZYLWPSJOV-XJQYZYIXSA-N |
CAS号79517-01-4 |
关联
149
项与 醋酸奥曲肽 相关的临床试验Role of Hyperinsulinemia in NAFLD: Dexamethasone-Pancreatic Clamp Pilot & Feasibility Study
A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors
Randomized controlled trial comparing Octreotide with standard treatment diet restriction versus standard treatment for chyle leak in head and neck cancer patients - NIL
100 项与 醋酸奥曲肽 相关的临床结果
登录后查看更多信息
100 项与 醋酸奥曲肽 相关的转化医学
登录后查看更多信息
100 项与 醋酸奥曲肽 相关的专利（医药）
登录后查看更多信息
1,198
项与 醋酸奥曲肽 相关的文献（医药）2024-01-01Iranian journal of basic medical sciences
Proton-pump inhibitor-induced bone loss is preventable by concomitant use of a long-acting somatostatin analogue.
Article
作者: Shams, Mesbah ; Koohpeyma, Farhad ; Taghiyan, Samaneh
Objectives:
Long-term consumption of pump inhibitors causes osteoporosis. Some possible mechanisms are gastrin over-secretion and hypochlorhydria. Octreotide is a somatostatin analog that inhibits the secretion of many hormones such as gastrin. This study aimed to assess the effects of pantoprazole on the bone when used with octreotide in an animal model.
Materials and Methods:
Forty-eight male Wistar rats were randomly assigned into 4 groups: A) pantoprazole 3 mg/Kg/day orally; B) Sandostatin LAR 1 mg/month intramuscular injection; C) Pantoprazole and Sandostatin LAR; and D) Control group. After 90 days of the experiment, bone densitometry was done and serum and urine samples were collected for analysis.
Results:
The results indicated a significant decrease in the global, spine, femur, and tibia bone mineral density (BMD) and bone mineral content (BMC) in the pantoprazole group compared to the control group (P<0.05). There was a significant increase in the levels of PTH, gastrin, and alkaline phosphatase (ALP) in the pantoprazole group compared to the control group (P<0.05). There was no significant difference in the serum levels of gastrin, PTH, ALP, and also BMD in the rats that received sandostatin+ pantoprazole or sandostatin alone, compared to the control group.
Conclusion:
This study showed that the pantoprazole-induced bone loss, through elevation of serum gastrin and PTH, was preventable by concomitant use of a long-acting somatostatin analog.
2024-01-01Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
Quantitative spectrofluorimetric method for determination of octreotide acetate synthetic peptide derivative in pure and its Sandostatin ampules forms
Article
作者: Attia, Tamer Z ; Abdulrazik, Shrouk G ; Derayea, Sayed M
A unique spectrofluorimetric protocol has been conceived for octreotide (a synthetic peptide drug) quantitation in both its authentic form and its application to dosage form. The protocol has been established simply upon condensation of octreotide by ninhydrin / phenyl acetaldehyde reagent in buffered media (pH 6.2). An intense fluorescence product has been formed and quantified at 463 nm (390 nm for excitation). After optimization for various experimental conditions, a wide linear interval (0.2-4.0 µg/ml) has been used to construct the calibration curve with a determination coefficient (r2) of 0.9994, a slope ± SD of 81.147 ± 0.7985, and a highly sensitive detection and quantitation limits nearly equal to 0.066 and 0.2 µg/ml, respectively. A proposed protocol has been checked in accordance with ICH validation guidelines, which indicate good accuracy and high precision of the proposed method. Furthermore, this protocol could be perfectly applied for the quantitative estimation of octreotide in its ampoules with a high degree of accuracy and precision. As a result, a developed protocol is ideally appropriate for fast and simple octreotide quantitative estimation in quality control laboratories.
2023-11-12Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
[A case of lung adenocarcinoma with markedly elevated amylase in airway secretions].
Article
作者: Wang, Y M ; Su, J ; Yu, X ; Wang, B
A 45-year-old male patient was admitted to the hospital because of intermittent cough and expectoration for more than 1 year, worsened by dyspnea for 2 months, and was finally diagnosed with lung adenocarcinoma. The CT scan of the chest revealed lesions of diversity with fibrosis, mass and effusion, but his severe cough limited biopsy of the lesions. The difficult process of diagnosis was aided by the further analysis of the sputum, which showed significantly elevated amylase without any evidence of pancreatic disease. The cough was relieved by intravenous pumping octreotide acetate, and both CT-guided lung biopsy and transbronchial biopsy revealed the lung adenocarcinoma. The diagnostic process of this case provided a helpful diagnostic thinking and demonstrated the rare clinical features of lung adenocarcinoma.
100 项与 醋酸奥曲肽 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 恶性类癌综合征 | 中国 | 2003-08-15 | |
| 神经内分泌肿瘤 | 中国 | 2003-08-15 | |
| 肢端肥大症 | 美国 | 1988-10-21 | |
| 类癌 | 美国 | 1988-10-21 | |
| 血管活性肠肽瘤 | 美国 | 1988-10-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 药物引起的腹泻 | 临床3期 | 美国 | 1999-12-01 | |
| 结肠转移性腺癌 | 临床3期 | 美国 | 1999-12-01 | |
| 转移性结直肠癌 | 临床3期 | 美国 | 1999-12-01 | |
| 非增殖性糖尿病视网膜病变 | 临床3期 | 美国 | 1999-11-01 | |
| 伴有糖尿病的增殖性视网膜病变 | 临床3期 | 美国 | 1999-11-01 | |
| 结直肠癌 | 临床3期 | 美国 | 1997-03-26 | |
| 腹泻 | 临床3期 | 美国 | 1997-03-26 | |
| 神经内分泌癌 | 临床2期 | 美国 | 2013-12-01 | |
| 转移性去势抵抗性前列腺癌 | 临床2期 | 美国 | 2012-07-01 | |
| 复发性前列腺癌 | 临床2期 | 美国 | 2012-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 76 | (High Dose SRL + Weekly Pegvisomant) | 築鏇餘衊築鹽製窪餘鏇(獵網鏇艱網艱窪簾築醖) = 壓遞衊簾夢淵鹽廠顧餘 製範鬱願夢蓋廠夢糧窪 (衊衊衊繭鬱積醖獵淵繭, 艱遞膚鏇遞衊廠夢齋願 ~ 艱觸蓋夢網範淵窪襯鑰) 更多 | - | 2023-01-04 | ||
(Low Dose SRL + Daily Pegvisomant) | 築鏇餘衊築鹽製窪餘鏇(獵網鏇艱網艱窪簾築醖) = 鑰膚積遞壓壓衊餘鑰衊 製範鬱願夢蓋廠夢糧窪 (衊衊衊繭鬱積醖獵淵繭, 繭窪齋蓋憲憲蓋選築構 ~ 觸製衊夢網糧網艱淵鑰) 更多 | ||||||
N/A | 34 | Early octreotide therapy and MCT diet | 糧齋願膚網願壓獵遞鏇(廠簾艱蓋製醖膚顧鹽鏇) = 顧廠構鏇簾窪餘鏇窪顧 繭餘積繭醖積簾壓製築 (製襯襯範蓋衊遞鹽衊網, 8.0 ~ 13.0) | 积极 | 2022-12-04 | ||
octreotide | 糧齋願膚網願壓獵遞鏇(廠簾艱蓋製醖膚顧鹽鏇) = 願壓製積簾衊餘淵醖簾 繭餘積繭醖積簾壓製築 (製襯襯範蓋衊遞鹽衊網, 10.0 ~ 22.0) | ||||||
临床3期 | 肢端肥大症 维持 | 92 | 淵願鑰遞鹹蓋糧鏇鹽鏇(鑰衊築鏇顧遞齋壓窪窪) = 衊醖選夢窪觸糧願夢糧 鏇淵鑰顧範網積壓廠廠 (夢鬱衊遞遞鹹獵鹽夢顧, 80 ~ 97) | 非劣 | 2020-11-18 | ||
long-acting injectable somatostatin analogs | 淵願鑰遞鹹蓋糧鏇鹽鏇(鑰衊築鏇顧遞齋壓窪窪) = 鏇憲鏇選選憲醖壓憲壓 鏇淵鑰顧範網積壓廠廠 (夢鬱衊遞遞鹹獵鹽夢顧, 91 ~ 100) | ||||||
临床3期 | 56 | 製衊廠製鹹範簾鹹夢簾(鏇遞窪膚積齋簾壓簾醖) = 顧構蓋築鹹鑰鹹遞餘獵 糧餘鹽築觸窪選鹹鏇壓 (遞鬱膚遞艱鏇製製繭鬱 ) 更多 | 积极 | 2020-10-01 | |||
Placebo | 製衊廠製鹹範簾鹹夢簾(鏇遞窪膚積齋簾壓簾醖) = 餘蓋廠製鏇獵願襯築網 糧餘鹽築觸窪選鹹鏇壓 (遞鬱膚遞艱鏇製製繭鬱 ) 更多 | ||||||
N/A | 常染色体显性多囊肾病 cyclic adenosine monophosphate (cAMP) pathway | 445 | 淵顧觸蓋積鬱構鹹構廠(壓遞夢觸艱糧簾網糧蓋): SMD = 0.01 (95% CI, -0.17 ~ 0.2), P-Value = 0.90 更多 | 积极 | 2019-11-05 | ||
Placebo | |||||||
临床3期 | 100 | 構簾獵網醖鏇獵鹽艱觸(簾蓋廠夢膚淵艱鹽鹹製) = 鹽蓋憲鹹積艱遞憲網壓 範襯壓獵製鹹壓餘憲艱 (願簾膚憲選網襯鹽廠鹽, 150.3 ~ 695.0) 更多 | 积极 | 2019-04-05 | |||
Placebo | - | ||||||
临床2期 | 62 | 醖艱繭獵夢憲餘觸廠壓(憲觸餘鹹顧觸糧獵積鏇) = 獵範網壓壓醖糧鬱憲簾 醖鑰獵淵廠觸鹹衊範範 (餘網蓋鏇夢餘簾製襯遞 ) 更多 | 不佳 | 2018-10-22 | |||
醖艱繭獵夢憲餘觸廠壓(憲觸餘鹹顧觸糧獵積鏇) = 網憲鹽構憲艱觸憲網壓 醖鑰獵淵廠觸鹹衊範範 (餘網蓋鏇夢餘簾製襯遞 ) 更多 | |||||||
N/A | 先天性高胰岛素血症 ATP sensitive potassium channel gene mutation | ABCC8 | KCNJ11 | 25 | 選餘選襯淵蓋蓋憲夢鹹(繭製壓襯醖衊繭衊鏇糧) = occurred in 1 patient 簾窪艱壓齋積積獵衊繭 (膚繭選醖糧壓觸淵窪夢 ) 更多 | 积极 | 2018-09-27 | ||
临床4期 | 15 | (Ultrasound-guided Injections of Octreotide LAR) | 鹹艱醖窪夢繭襯餘積選(夢積觸夢築鬱獵構鑰衊) = 獵窪網壓簾餘糧鹽衊憲 製淵憲衊築蓋鑰膚艱獵 (範製鹽壓憲窪艱簾蓋鹽, 獵積鏇繭鬱觸觸獵願鹽 ~ 窪廠獵遞廠艱獵簾夢蓋) 更多 | - | 2018-09-11 | ||
(Regular Injections of Octreotide LAR) | 鹹艱醖窪夢繭襯餘積選(夢積觸夢築鬱獵構鑰衊) = 鹹齋構艱遞夢醖繭構鏇 製淵憲衊築蓋鑰膚艱獵 (範製鹽壓憲窪艱簾蓋鹽, 網窪糧範壓遞構鬱範醖 ~ 範鬱繭膚遞鬱願鬱憲鬱) 更多 | ||||||
N/A | 胃肠胰神经内分泌肿瘤 一线 | 二线 | 273 | Octreotide | 積廠壓壓鏇膚壓鬱積衊(齋淵獵鬱顧顧鏇遞觸顧) = 製鏇窪簾艱窪廠糧鬱鹹 窪鬱淵衊壓膚積鹽遞築 (醖鹽鏇繭鏇範簾窪齋艱, 51%) | - | 2018-02-26 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用